CRISPR Therapeutics AG
NASDAQ:CRSP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
40.385
89.12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
CRISPR Therapeutics AG
CRISPR Therapeutics AG
Other Current Assets
CRISPR Therapeutics AG
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Other Current Assets
$8.2m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Other Current Assets
$16.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Other Current Assets
CHf3.4m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Molecular Partners AG
SIX:MOLN
|
Other Current Assets
CHf3.1m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Other Current Assets
CHf11.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Other Current Assets
CHf1.7m
|
CAGR 3-Years
32%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
Glance View
CRISPR Therapeutics AG is at the forefront of revolutionizing modern medicine through gene-editing technology. Founded on the groundbreaking research of CRISPR-Cas9, a tool that allows scientists to precisely alter an organism’s DNA, the company has swiftly emerged as a leader in the biotech arena. Situated in Switzerland, with significant operations in the United States, CRISPR Therapeutics aims to translate this cutting-edge science into transformative therapies. Its portfolio highlights collaborative efforts with other industry giants to develop treatments for serious genetic diseases, such as its flagship program targeting sickle cell disease and beta-thalassemia. By leveraging its proprietary CRISPR platform, the company focuses on developing gene-based medicines that address the root causes of illnesses, marking a departure from traditional symptom management to potentially groundbreaking cures. The business model of CRISPR Therapeutics is both innovative and strategic. Monetization is achieved through a blend of partnerships, licensing agreements, and direct therapeutic development. The company collaborates with various pharmaceutical entities, creating a network of shared knowledge and resources that accelerates the commercialization of therapies. These alliances facilitate shared risk and reward, allowing CRISPR Therapeutics to generate revenue while advancing its research and development pipeline. Moreover, the successful progression of any internally-developed therapies into approved treatments has the potential to unlock significant financial returns, both from sales and potential royalties. True to its visionary roots, CRISPR Therapeutics not only pursues immediate financial success but also seeks to redefine the landscape of genetic medicine with the long-term goal of delivering curative treatments for numerous genetic conditions.
See Also
What is CRISPR Therapeutics AG's Other Current Assets?
Other Current Assets
8.2m
USD
Based on the financial report for Sep 30, 2024, CRISPR Therapeutics AG's Other Current Assets amounts to 8.2m USD.
What is CRISPR Therapeutics AG's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-25%
Over the last year, the Other Current Assets growth was -60%. The average annual Other Current Assets growth rates for CRISPR Therapeutics AG have been -42% over the past three years , -25% over the past five years .
You don't have any saved screeners yet
